Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Q1 Revenues to Miss Wall Street Estimates

NEW YORK (GenomeWeb News) — Affymetrix said today that it expects to report total revenues of approximately $78 million for the first quarter when it releases its financial results later this month.

The preliminary revenues missed the average Wall Street estimate of $83.3 million for the quarter.

Affymetrix did not provide first quarter guidance when it reported its fourth-quarter and full-year 2012 revenues in February. Though the firm's Q1 2013 revenues grew by about 20 percent compared to its first-quarter 2012 revenues, the most recent quarter included a $19 million contribution from Affymetrix's eBioscience business, which it acquired last June.

"Our revenues for the first quarter were below expectations, primarily due to continued headwinds in our gene expression business across all regions, in particular Japan, where we came in significantly short of plan," Affymetrix President and CEO Frank Witney said in a statement.

At the same time, Witney said that Affymetrix's genotyping and cytogenetics product lines "generated solid growth" during the quarter, and that eBioscience has "modest growth" compared to Q1 2012.

Affymetrix filed its CytoScan product for the detection of constitutional abnormalities with the US Food and Drug Administration during the quarter.

Witney also noted in the statement that Affymetrix ended Q1 with a "major win" by securing a 500,000-sample genotyping deal with UK Biobank last month.

Affymetrix recently eliminated 100 positions, or 8 percent of its workforce. The company said at the time that the restructuring would allow it to save about $25 million on an annualized basis.

As of March 31, Affymetrix said it had cash on hand of about $38 million, after redeeming the remaining $3.9 million of its 3.5 percent convertible notes and prepaying $3.2 million of its senior-secured debt. CFO Tim Barabe said in a statement that the company's senior secured debt is now $70 million and that "debt repayment continues to be one of our priorities in 2013."

The firm said it will provide a more detailed business update when it reports its Q1 results on April 30.

In Tuesday morning trade on the Nasdaq, shares of Affymetrix were down around 15 percent at $3.98.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.